CA
NZ
UK
AU
IND
US
Chairman and Chief Executive Officer Robert Davis said the science-led strategy is transforming the business, pointing to oncology data presented at the ESMO congress for the antibody-drug conjugate sac-TMT and a first Phase 3 validation of a therapeutic cancer vaccine.
Sales growth came from higherVolumeof USD 8.9 million and higher pricing of USD 4.2 million, partly offset by USD 0.2 million of unfavorable currency translation.Operating Incomefrom continuing operations fell 11.2% to USD 14.8 million, and income from continuing operations was USD 4.7 million against …
NetYieldfell 6.5% as reported and 6.7% in constant currency, about 220 basis points better than the 8.9% decline the company had guided to. Chairperson and Chief Executive Officer John Chidsey attributed the result to stronger close-in demand from consumers who deferred summer trips, plus …
Total net income of USD 573.8 million, before USD 418.5 million attributed to non-controlling interests, reflected a derivative gain of USD 851.2 million versus a USD 74.1 million loss a year earlier. The company attributed the swing to higher forward SOFR rates, which raised …
Management Services, Servicing Fees, and Other revenue rose 18.3% to USD 376.3 million, the fifth consecutive record quarter for those businesses, and the servicing and asset management portfolio grew 23.2%. Leasing and Other Commissions gained 26.5%, the best third quarter on record, led byDemandtied …
Net loss narrowed to USD 1 million from USD 20 million, and operating loss shrank to USD 2 million from USD 25 million. AdjustedNet Incomewas USD 8 million against an adjusted net loss of USD 8 million a year earlier.
The company said the increase in revenue came from a 19% rise in active patients and a one time benefit of about USD 4 million from higher approval rates in the United States and Germany, partly offset by a USD 2 million currency headwind.
GAAPNet Incomewas USD 11 million versus USD 5 million, and non-GAAP net income was USD 27 million versus USD 24 million. Revenue landed above the high end of the prior guidance range of USD 301 million to USD 307 million.
Access segment sales jumped 20.7% to USD 1,339.6 million, withOperating Incomeup 23.5% to USD 145.7 million and a margin of 10.9%. North AmericaVolumeadded USD 207 million and pricing added USD 31 million. Orders reached USD 2.0 billion for a book to bill ratio of …
Fee-related earnings rose 14% to USD 427.5 million, or USD 0.27 per adjusted share, and distributable earnings increased 13% to USD 385.5 million. Management fees under GAAP reached USD 678.3 million, up 5%, while administrative, transaction and other fees jumped 66% to USD 136.7 …
Please wait processing your request...